2 weeks Ago By ABMN Staff
Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO – Get Free Report ) shares gapped down prior to trading on Friday . The stock had previously closed at $48.
05, but opened at $45.57. Agios Pharmaceuticals shares last traded at $43.
64, with a volume of 513,555 shares. Analyst Ratings Changes AGIO has been the subject of several research reports. The Goldman Sachs Group raised their target price on Agios Pharmaceuticals from $33.
00 to $53.00 and gave the company a “neutral” rating in a research note on Tuesday, June 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th.
Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $60.00 to $56.00 in a report on Friday.
Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 19th.
One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $52.50.
Check Out Our Latest Report on AGIO Agios Pharmaceuticals Trading Down 5.1 % Agios Pharmaceuticals ( NASDAQ:AGIO – Get Free Report ) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.
69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09).
The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million.
Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%.
The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.
51) EPS. As a group, research analysts expect that Agios Pharmaceuticals, Inc. will post -4.
85 EPS for the current year. Insider Transactions at Agios Pharmaceuticals In other Agios Pharmaceuticals news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.
75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358.
The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . 4.93% of the stock is currently owned by corporate insiders.
Institutional Trading of Agios Pharmaceuticals A number of hedge funds have recently modified their holdings of the company. Norges Bank acquired a new stake in Agios Pharmaceuticals during the fourth quarter worth $6,826,000. Allianz Asset Management GmbH increased its stake in shares of Agios Pharmaceuticals by 38.
8% in the fourth quarter. Allianz Asset Management GmbH now owns 149,111 shares of the biopharmaceutical company’s stock valued at $3,321,000 after buying an additional 41,701 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at about $951,000.
NEOS Investment Management LLC acquired a new position in Agios Pharmaceuticals during the 4th quarter worth about $210,000. Finally, Rafferty Asset Management LLC increased its position in Agios Pharmaceuticals by 14.9% in the 4th quarter.
Rafferty Asset Management LLC now owns 153,485 shares of the biopharmaceutical company’s stock valued at $3,418,000 after acquiring an additional 19,861 shares in the last quarter. Agios Pharmaceuticals Company Profile ( Get Free Report ) Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Stories Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
